<DOC>
	<DOC>NCT00436228</DOC>
	<brief_summary>SB-742510 is a semi-synthetic pleuromutilin antibiotic that is being developed for treatment of respiratory infections. The purpose of this study is to estimate the bioavailability of four different formulations and to evaluate the safety of each of the four formulations</brief_summary>
	<brief_title>To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug</brief_title>
	<detailed_description />
	<criteria>Healthy as determined by a responsible physician, based on medical evaluations performed at screening. Healthy adults between 18 and 60 years of age, inclusive. Body weight proportional to height. Capable of giving written informed consent. Female subjects must be of nonchildbearing potential. QTc less than 450 msec at screening Any clinically relevant abnormality identified on the screening history and physical or on the 12lead surface electrocardiogram at screening or predose. The subject has a positive prestudy alcohol/urine drug screen. History of regular use of tobacco, or nicotinecontaining products. A positive prestudy HIV antibody, Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody result within 3 months of screening. Use of certain prescription or nonprescription drugs, including vitamins, herbal and dietary supplements. An unwillingness to comply with lifestyle and/or dietary restrictions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>healthy volunteer,</keyword>
	<keyword>Bioavailability,</keyword>
	<keyword>safety</keyword>
	<keyword>Phase I,</keyword>
</DOC>